Jonathan A. Kropski

Jonathan A. Kropski

Auto-generated profile, based on publicly available information

Jonathan A. Kropski

Vanderbilt University Medical Center Department of Medicine Nashville, TN

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
AHArun C. Habermann
Arun C. Habermann
AGAustin J. Gutierrez
Austin J. Gutierrez
LBLinh T. Bui
Linh T. Bui
SYStephanie L. Yahn
Stephanie L. Yahn
NWNichelle I. Winters
Nichelle I. Winters
JKJonathan A. Kropski
Jonathan A. Kropski
Pulmonary fibrosis (PF) is a form of chronic lung disease characterized by pathologic epithelial remodeling and accumulation of extracellular matrix (ECM). To comprehensively define the cell types, mechanisms, and mediators driving fibrotic remodeling in lungs with PF, we performed single-cell RNA sequencing of single-cell suspensions from 10 nonfibrotic control and 20 PF lungs. Analysis of 114,396 cells identified 31 distinct cell subsets/states. We report that a remarkable shift in epithelial cell phenotypes occurs in the peripheral lung in PF and identify several previously unrecognized epithelial cell phenotypes, including a KRT5−/KRT17+ pathologic, ECM-producing epithelial cell population that was highly enriched in PF lungs. Multiple fibroblast subtypes were observed to contribute to ECM expansion in a spatially discrete manner. Together, these data provide high-resolution insights into the complexity and plasticity of the distal lung epithelium in human disease and indicate a diversity of epithelial and mesenchymal cells contribute to pathologic lung fibrosis.

8 June 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
LSLisa Sikkema
Lisa Sikkema
CRCiro Ramírez-Suástegui
Ciro Ramírez-Suástegui
DSDaniel C. Strobl
Daniel C. Strobl
TGTessa E. Gillett
Tessa E. Gillett
LZLuke Zappia
Luke Zappia
FTFabian J. Theis
Fabian J. Theis
Single-cell technologies have transformed our understanding of human tissues. Yet, studies typically capture only a limited number of donors and disagree on cell type definitions. Integrating many single-cell datasets can address these limitations of individual studies and capture the variability present in the population. Here we present the integrated Human Lung Cell Atlas (HLCA), combining 49 datasets of the human respiratory system into a single atlas spanning over 2.4 million cells from 486 individuals. The HLCA presents a consensus cell type re-annotation with matching marker genes, including annotations of rare and previously undescribed cell types. Leveraging the number and diversity of individuals in the HLCA, we identify gene modules that are associated with demographic covariates such as age, sex and body mass index, as well as gene modules changing expression along the proximal-to-distal axis of the bronchial tree. Mapping new data to the HLCA enables rapid data annotation and interpretation. Using the HLCA as a reference for the study of disease, we identify shared cell states across multiple lung diseases, including SPP1+ profibrotic monocyte-derived macrophages in COVID-19, pulmonary fibrosis and lung carcinoma. Overall, the HLCA serves as an example for the development and use of large-scale, cross-dataset organ atlases within the Human Cell Atlas.

13 July 2020 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
YKYoshihiko Kobayashi
Yoshihiko Kobayashi
ATAleksandra Tata
Aleksandra Tata
AKArvind Konkimalla
Arvind Konkimalla
HKHiroaki Katsura
Hiroaki Katsura
RLRebecca F. Lee
Rebecca F. Lee
PTPurushothama Rao Tata
Purushothama Rao Tata

27 July 2021 in Circulation
Verified
Journal Article
Open access
PDF file
JSJonas C. Schupp
Jonas C. Schupp
TATaylor S. Adams
Taylor S. Adams
CCCarlos Cosme
Carlos Cosme
MRMicha Sam Brickman Raredon
Micha Sam Brickman Raredon
YYYifan Yuan
Yifan Yuan
NKNaftali Kaminski
Naftali Kaminski
Background: Cellular diversity of the lung endothelium has not been systematically characterized in humans. We provide a reference atlas of human lung endothelial cells (ECs) to facilitate a better understanding of the phenotypic diversity and composition of cells comprising the lung endothelium. Methods: We reprocessed human control single-cell RNA sequencing (scRNAseq) data from 6 datasets. EC populations were characterized through iterative clustering with subsequent differential expression analysis. Marker genes were validated by fluorescent microscopy and in situ hybridization. scRNAseq of primary lung ECs cultured in vitro was performed. The signaling network between different lung cell types was studied. For cross-species analysis or disease relevance, we applied the same methods to scRNAseq data obtained from mouse lungs or from human lungs with pulmonary hypertension. Results: Six lung scRNAseq datasets were reanalyzed and annotated to identify >15 000 vascular EC cells from 73 individuals. Differential expression analysis of EC revealed signatures corresponding to endothelial lineage, including panendothelial, panvascular, and subpopulation-specific marker gene sets. Beyond the broad cellular categories of lymphatic, capillary, arterial, and venous ECs, we found previously indistinguishable subpopulations; among venous EC, we identified 2 previously indistinguishable populations: pulmonary–venous ECs (COL15A1 neg ) localized to the lung parenchyma and systemic–venous ECs (COL15A1 pos ) localized to the airways and the visceral pleura; among capillary ECs, we confirmed their subclassification into recently discovered aerocytes characterized by EDNRB , SOSTDC1 , and TBX2 and general capillary EC. We confirmed that all 6 endothelial cell types, including the systemic–venous ECs and aerocytes, are present in mice and identified endothelial marker genes conserved in humans and mice. Ligand-receptor connectome analysis revealed important homeostatic crosstalk of EC with other lung resident cell types. scRNAseq of commercially available primary lung ECs demonstrated a loss of their native lung phenotype in culture. scRNAseq revealed that endothelial diversity is maintained in pulmonary hypertension. Our article is accompanied by an online data mining tool ( www.LungEndothelialCellAtlas.com ). Conclusions: Our integrated analysis provides a comprehensive and well-crafted reference atlas of ECs in the normal lung and confirms and describes in detail previously unrecognized endothelial populations across a large number of humans and mice.

1 October 2018 in Matrix Biology
Verified
Journal Article
Closed access
JHJustin C. Hewlett
Justin C. Hewlett
JKJonathan A. Kropski
Jonathan A. Kropski
TBTimothy S. Blackwell
Timothy S. Blackwell

2 January 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JKJonathan A. Kropski
Jonathan A. Kropski
TBTimothy S. Blackwell
Timothy S. Blackwell
Eukaryotic cells contain an elegant protein quality control system that is crucial in maintaining cellular homeostasis; however, dysfunction of this system results in endoplasmic reticulum (ER) stress and activation of the unfolded protein response (UPR). Severe or prolonged ER stress is associated with the development of degenerative and fibrotic disorders in multiple organs, as evidenced by the identification of disease-causing mutations in epithelial-restricted genes that lead to protein misfolding or mistrafficking in familial fibrotic diseases. Emerging evidence implicates ER stress and UPR signaling in a variety of profibrotic mechanisms in individual cell types. In epithelial cells, ER stress can induce apoptosis, inflammatory signaling, and epithelial-mesenchymal transition. In other cell types, ER stress is linked to myofibroblast activation, macrophage polarization, and T cell differentiation. ER stress–targeted therapies have begun to emerge using approaches that range from global enhancement of chaperone function to selective targeting of activated ER stress sensors and other downstream mediators. As the complex regulatory mechanisms of this system are further clarified, there are opportunities to develop new disease-modifying therapeutic strategies in a wide range of chronic fibrotic diseases.